Tecan Group (TECN) H1 2025 earnings summary

Executive summary

• H1 2025 revenue was CHF 439.5 million, with adjusted EBITDA of CHF 65.7 million and a 15% margin, meeting expectations despite market headwinds.

• Operational resilience was enhanced through cost reduction, site consolidation, supply chain optimization, and new product launches such as the Multi Omics Veya workstation.

• CEO transition completed with Monica Manotas taking over in August 2025, focusing on sustainable growth and innovation.

• New partnerships, major manufacturing contracts, and MedTech collaborations were secured, supporting future growth.

Financial highlights

• Order entry for H1 2025 was CHF 458.3 million, down 2.9% year-on-year, but book-to-bill ratio returned to or above 1, indicating improved order momentum.

• Revenue declined 5.9% in CHF and 3.7% in local currencies year-on-year, with sequential improvement in Q2.

• Gross profit margin improved by 180 bps to 36.2% due to favorable mix, price increases, and efficiency gains.

• Adjusted EBITDA margin rose by 50 bps to 15% despite lower sales volume and FX headwinds.

• Adjusted net profit was CHF 33.7 million; reported net profit was CHF 17.9 million.

• Cash flow from operating activities was CHF 60 million, with net liquidity at CHF 140.3 million as of June 30, 2025.

Outlook and guidance

• Full-year 2025 sales outlook confirmed: local currency sales expected in a range from low single-digit decline to low single-digit growth.

• Adjusted EBITDA margin forecast reiterated at 17.5%-18.5% of sales, excluding U.S. tariff impacts.

• Tariffs could have a low teens million CHF impact on EBITDA for 2025; mitigation measures underway.

• FX rates could reduce margin by 80-100 bps if current levels persist.

• Mid-term outlook anticipates a return to mid- to high-single-digit organic growth rates in local currencies and continuous profitability improvement.